A desk reference, not a clinic.

What KLOW MD is

KLOW MD is a desk-reference file on the KLOW four-peptide research blend and its four constituents — KPV, GHK-Cu, BPC-157, and TB-500. It reads the peer-reviewed record and lays it out entry by entry, the way a monograph does. No clinician staffs it, no advice is issued from it, and nothing it describes is for sale, supply, or shipment; it holds no tie to any vendor, compounder, or pharmacy.

The 'MD' in the domain is desk-reference framing — how a physician's-desk-reference entry catalogs a substance — not a representation that the publisher holds a medical license or runs a practice. Every line here traces a published study; the writing stays commentary on science that is already in the open literature.

Why this site exists

KLOW is an unusual subject. It is sold by compounders and research-chemical vendors as a single co-formulation, but it has the literature footprint of four separate compounds — each with its own decades-long paper trail, its own regulatory status, and its own evidence ceiling. No controlled study has tested the four-peptide blend against monotherapy of any single component, against any pairwise or three-peptide subset, or against placebo.

Most online writing about KLOW treats the four peptides as one substance and reasons about their combined effects from mechanistic plausibility alone. This site does the opposite. It treats the blend as four monographs in a single shell, surfaces the combination-evidence gap as a primary editorial callout, and presents each component on the same level of restraint the underlying literature uses.

Editorial standards

Every quantitative claim on this site — dose values, half-life numbers, study counts, percentages, gene-expression figures — is sourced to a specific paper, identified by author, journal, year, DOI, and PubMed link. The complete reference list is on the /references page. Inline [N] markers connect every claim in the body text to the underlying citation.

We do not write recommended human doses. Where the literature reports an experimental dose, we report it in the third person as the dose used in that specific study. We do not refer to clinics or providers we have no affiliation with. We do not link to vendors, compounders, or supplement marketing pages. We do not use competitor brand names.

Sourcing methodology

We prioritize peer-reviewed primary literature (PubMed, PubMed Central), authoritative regulatory records (FDA bulk-substance lists, WADA prohibited-list entries), and recent systematic and narrative reviews. Where preclinical work dominates a component's evidence base — which is the case for all four KLOW peptides — we are explicit about species, route, and dose, and about the gap between preclinical evidence and human data. Where a component's most-cited 'mechanism' data was generated with a different molecule than the one marketed under the KLOW name (the TB-500-versus-native-Tβ4 distinction is the clearest example), we surface that distinction in the body text rather than blurring it.

Where this file stops

Nothing is sold here, and no prescription is written here. The file points to no clinic, compounder, telehealth service, or research-chemical seller, and it hands out no personalized medical, scientific, or research guidance. It does not read the KLOW literature as a treatment plan. For clinical direction, this is the wrong desk — take that to a licensed clinician.

Everything on these pages is research-only commentary on already-published science, and the full disclaimer sits in the footer of every page.